# 2026-08791: NIH Hands Cancer Cure Tech to Startup, Sparking Treatment Race

2026-08791, Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-05-06, effective 2026-05-21 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08791
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08791
- Title: Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 24551
- Published: 2026-05-06
- Effective: 2026-05-21
- Comments close: 2026-05-21
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

NIH Hands Cancer Cure Tech to Startup, Sparking Treatment Race

## Summary

The National Cancer Institute plans to give OncoVanta Therapeutics an exclusive license to develop and sell special engineered cell therapies that target cancer. This means OncoVanta will have the sole right to use these patented inventions, which could speed up new cancer treatments. Anyone interested must send comments or license requests by May 21, 2026.

## Abstract

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OncoVanta Therapeutics, Inc. ("OncoVanta"), a company located in Hagerstown, Maryland, the United States of America.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-08791 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/06/2026-08791/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-engineered)
- [2026-08791 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-06/pdf/2026-08791.pdf)

## Related
- [Previous: 2026-08790, Notice of Agreements Filed](https://policyrisk.com/federal-register/2026-08790)
- [Next: 2026-08792, Notice to All Interested Parties of Intent To Terminate Receiverships](https://policyrisk.com/federal-register/2026-08792)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08791 (as of 2026-06-08).
